OriC633–05

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameOriC633–05
Drug Alias NameOriC633–05
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Glypican-3Alpha-fetoprotein modulatorsHLA class I histocompatibility antigen, A alpha chain modulators
TargetsGlypican-3Alpha-fetoproteinHLA class I histocompatibility antigen, A alpha chain
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesOriCell Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOriCell Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A